HMPV Vs RSV: Understanding The Differences Between Two Major Respiratory Viruses

Advances in vaccine development provide optimism for lowering the prevalence of RSV and, eventually, HMPV.

Respiratory viruses play a crucial role in infections affecting children, the elderly, and immunocompromised individuals. Two significant causes are human metapneumovirus (HMPV) and respiratory syncytial virus (RSV). Although they are members of the same Pneumovirus family, these viruses have distinct epidemiological patterns, age-related impacts, and disease severity. Understanding these characteristics is critical for successful diagnosis and management.

Overview Of The Viruses

• RSV primarily affects infants under six months of age, often resulting in severe bronchiolitis and pneumonia. In this age group, RSV infections are the primary cause of hospitalization worldwide. Infants born prematurely or with underlying problems such as congenital heart disease or chronic lung illness require critical care.
• In contrast, HMPV significantly influences slightly older infants, often aged six to twelve months. Furthermore, HMPV affects a broader population, including older children, adults, and especially elderly persons with chronic health issues or weakened immune systems. HMPV is also known to worsen chronic respiratory disorders such as asthma and COPD, making it a significant concern in adult pulmonology.

Who Is Most Affected?

• RSV primarily targets infants under six months of age, often leading to severe bronchiolitis and pneumonia. In this age group, RSV infections are a leading cause of hospitalization worldwide. Infants born prematurely or with underlying conditions like congenital heart disease or chronic lung disease face a heightened risk of severe RSV infections, which may require intensive care.
• In contrast, HMPV tends to significantly impact slightly older infants, typically between six and twelve months. Furthermore, HMPV affects a broader demographic range, including older children and adults, particularly older adults with chronic health conditions or compromised immune systems. HMPV is also known to exacerbate chronic respiratory conditions like asthma and COPD, making it a substantial concern for adult pulmonology.

Diagnosis And Testing

• Given the overlap in symptoms, laboratory testing is required to distinguish between RSV and HMPV, the gold standard for detecting both viruses. While quick antigen tests are available for RSV, their sensitivity varies, especially in older children and adults.
• Unfortunately, no analogous fast assays exist for HMPV; hence, PCR is the primary diagnosis method. Early and correct identification aids clinical management and reduces the unnecessary use of antibiotics, which are ineffective against viral infections.

Treatment Options

RSV and HMPV are treated chiefly with supportive measures. In mild cases, symptomatic therapy such as hydration, fever management, and nasal suctioning is usually sufficient. In more severe cases, hospitalization may be necessary to administer oxygen therapy, intravenous fluids, or mechanical ventilation.